NCT04947124View on ClinicalTrials.gov

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

June 6, 2022

Study Completion Date

August 1, 2022

Conditions
Sturge-Weber Syndrome (SWS)GlaucomaGlaucoma CongenitalOcular Hypertension
Interventions
DRUG

QLS-101ophthalmic solution 1%

QLS-101ophthalmic solution 1.0%

DRUG

QLS-101ophthalmic solution 2%

QLS-101ophthalmic solution 2.0%

Trial Locations (1)

27710

Duke Eye Center, Durham

All Listed Sponsors
lead

Qlaris Bio, Inc.

INDUSTRY

NCT04947124 - A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 | Biotech Hunter | Biotech Hunter